Literature DB >> 22823482

Acute treatment of migraines.

Arnaldo N Da Silva1, Stewart J Tepper.   

Abstract

Migraine is a prevalent and disabling brain disorder that costs billions of dollars annually in direct healthcare costs, and school and work absenteeism and presenteeism. The objective of acute treatment is a cost-effective, rapid restoration of functional ability, with minimal recurrence and adverse effects. The acute treatment of migraine includes specific drugs, which currently all have vasoconstrictive effects (dihydroergotamine and triptans), and nonspecific drugs that include paracetamol (acetaminophen), combination analgesics, non-steroidal anti-inflammatory drugs (NSAIDs), dopamine antagonists, narcotics and corticosteroids. NSAIDs have both peripheral and central effects on reversing migraine, and so may represent the best alternative for patients who cannot use triptans and ergots due to vascular contraindications. Narcotics and habituating medications should be avoided in the acute treatment of migraine, as the risk for transformation to chronic daily headache is excessively high at a relatively infrequent rate of exposure.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22823482     DOI: 10.2165/11635440-000000000-00000

Source DB:  PubMed          Journal:  CNS Drugs        ISSN: 1172-7047            Impact factor:   5.749


  90 in total

Review 1.  Rescue therapy for acute migraine, part 3: opioids, NSAIDs, steroids, and post-discharge medications.

Authors:  Nancy E Kelley; Deborah E Tepper
Journal:  Headache       Date:  2012-03       Impact factor: 5.887

2.  Prevalence and burden of migraine in the United States: data from the American Migraine Study II.

Authors:  R B Lipton; W F Stewart; S Diamond; M L Diamond; M Reed
Journal:  Headache       Date:  2001 Jul-Aug       Impact factor: 5.887

Review 3.  Development and testing of the Migraine Disability Assessment (MIDAS) Questionnaire to assess headache-related disability.

Authors:  W F Stewart; R B Lipton; A J Dowson; J Sawyer
Journal:  Neurology       Date:  2001       Impact factor: 9.910

4.  Abortive headache therapy in the office with intravenous dihydroergotamine plus prochlorperazine.

Authors:  H A Saadah
Journal:  Headache       Date:  1992-03       Impact factor: 5.887

5.  The fixed combination of acetylsalicylic acid, paracetamol and caffeine is more effective than single substances and dual combination for the treatment of headache: a multicentre, randomized, double-blind, single-dose, placebo-controlled parallel group study.

Authors:  H C Diener; V Pfaffenrath; L Pageler; H Peil; B Aicher
Journal:  Cephalalgia       Date:  2005-10       Impact factor: 6.292

6.  Venoconstrictor responses to dihydroergocristine and dihydroergotamine: evidence for the involvement of 5-HT1 like receptors.

Authors:  E Müller-Schweinitzer
Journal:  Cardiovasc Drugs Ther       Date:  1990-12       Impact factor: 3.727

7.  Stratified care vs step care strategies for migraine: the Disability in Strategies of Care (DISC) Study: A randomized trial.

Authors:  R B Lipton; W F Stewart; A M Stone; M J Láinez; J P Sawyer
Journal:  JAMA       Date:  2000 Nov 22-29       Impact factor: 56.272

8.  Prevalence and diagnosis of migraine in patients consulting their physician with a complaint of headache: data from the Landmark Study.

Authors:  Stewart J Tepper; Carl G H Dahlöf; Andrew Dowson; Lawrence Newman; Hank Mansbach; Martin Jones; Ba Pham; Chris Webster; Reijo Salonen
Journal:  Headache       Date:  2004-10       Impact factor: 5.887

Review 9.  Safety and efficacy of ergotamine tartrate and dihydroergotamine in the treatment of migraine and status migrainosus. Working Panel of the Headache and Facial Pain Section of the American Academy of Neurology.

Authors:  S D Silberstein; W B Young
Journal:  Neurology       Date:  1995-03       Impact factor: 9.910

Review 10.  Advances in the basic and clinical science of migraine.

Authors:  Andrew Charles
Journal:  Ann Neurol       Date:  2009-05       Impact factor: 10.422

View more
  6 in total

Review 1.  Migraine and reward system-or is it aversive?

Authors:  Catherine M Cahill; Christopher Cook; Sarah Pickens
Journal:  Curr Pain Headache Rep       Date:  2014-05

Review 2.  Sumatriptan/naproxen sodium: a review of its use in adult patients with migraine.

Authors:  Lily P H Yang
Journal:  Drugs       Date:  2013-08       Impact factor: 9.546

3.  Remote Electrical Neuromodulation (REN) Relieves Acute Migraine: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial.

Authors:  David Yarnitsky; David W Dodick; Brian M Grosberg; Rami Burstein; Alon Ironi; Dagan Harris; Tamar Lin; Stephen D Silberstein
Journal:  Headache       Date:  2019-05-09       Impact factor: 5.887

4.  Remote Electrical Neuromodulation for the Acute Treatment of Migraine in Patients with Chronic Migraine: An Open-Label Pilot Study.

Authors:  Hida Nierenburg; Julio R Vieira; Nirit Lev; Tamar Lin; Dagan Harris; Maya Vizel; Alon Ironi; Bryan Lewis; Paul Wright
Journal:  Pain Ther       Date:  2020-07-09

5.  Real-World Analysis of Remote Electrical Neuromodulation (REN) for the Acute Treatment of Migraine.

Authors:  Jessica Ailani; Liron Rabany; Shira Tamir; Alon Ironi; Amaal Starling
Journal:  Front Pain Res (Lausanne)       Date:  2022-01-18

6.  Theory-based analysis of clinical efficacy of triptans using receptor occupancy.

Authors:  Kentaro Tokuoka; Risa Takayanagi; Yuji Suzuki; Masayuki Watanabe; Yasuhisa Kitagawa; Yasuhiko Yamada
Journal:  J Headache Pain       Date:  2014-12-08       Impact factor: 7.277

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.